Accordingly, specific studies on this issue with this type of COVID-19 vaccine should be considered by closely monitoring the response patterns of HIV-infected people to various immune parameters, which would include periodically measuring CD4 T-cell counts, viral loads, and anti-spike protein antibody levels subsequent to being vaccinated. This evidence concerns the gene CD4 and COVID-19.